These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34068847)

  • 21. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C; Chai KL; Piechotta V; Valk SJ; Kimber C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Jindal A; Cryns N; Estcourt LJ; Kreuzberger N; Skoetz N
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013600. PubMed ID: 36734509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
    Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
    mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.
    Rodríguez-Rubio M; Figueira JC; Acuña-Castroviejo D; Borobia AM; Escames G; de la Oliva P
    Trials; 2020 Aug; 21(1):699. PubMed ID: 32758298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.
    AlShehry N; Zaidi SZA; AlAskar A; Al Odayani A; Alotaibi JM; AlSagheir A; Al-Eyadhy A; Balelah S; Salam A; Zaidi ARZ; Alawami D; Alshahrani MS; AlMozain N; Abulhamayel YM; Al Qunfoidi R; Alfaraj M; Qushmaq N; Alansari R; Dayel A; Elgohary G; Al Bahrani A; Nabhan Abdelhameed AA; AlZahrani HA; Alturkistani H; AlShehry N; Albalawi MA; Elalfy I; Alhumaidan H; Al-Hashmi H;
    Saudi J Med Med Sci; 2021; 9(1):16-23. PubMed ID: 33519339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe Acute Kidney Injury in Critically Ill Patients with COVID-19 Admitted to ICU: Incidence, Risk Factors, and Outcomes.
    Ghosn M; Attallah N; Badr M; Abdallah K; De Oliveira B; Nadeem A; Varghese Y; Munde D; Salam S; Abduljawad B; Saleh K; Elkambergy H; Wahla A; Taha A; Dibu J; Bayrlee A; Hamed F; Rahman N; Mallat J
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33804100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma.
    Perichon AM; Acosta A; Di Tulio L; Munuce MJ; Pezzotto S; Bottasso O; Nannini EC
    mBio; 2023 Dec; 14(6):e0177723. PubMed ID: 37938024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Convalescent Plasma in the Management of Critically Ill COVID-19 Patients (with No Detectable Neutralizing Antibodies Nab) in Kashmir, India.
    Elkhalifa AME; Nabi SU; Shah NN; Dar KA; Quibtiya S; Bashir SM; Ali SI; Taifa S; Hussain I
    Healthcare (Basel); 2023 Jan; 11(3):. PubMed ID: 36766892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis.
    Jorda A; Kussmann M; Kolenchery N; Siller-Matula JM; Zeitlinger M; Jilma B; Gelbenegger G
    Front Immunol; 2022; 13():817829. PubMed ID: 35197981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
    JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
    Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
    Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of convalescent plasma according to blood groups in COVID-19 patients.
    Hacibekiroğlu T; Kalpakçı Y; Genç AC; Hacibekiroğlu İ; Sunu C; Saricaoğlu A; Tomak Y; Karabay O; Köroğlu M
    Turk J Med Sci; 2021 Feb; 51(1):45-48. PubMed ID: 32950044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19-A Retrospective Study.
    Roedl K; Söffker G; Wichmann D; Boenisch O; de Heer G; Burdelski C; Frings D; Sensen B; Nierhaus A; Westermann D; Kluge S; Jarczak D
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34069530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial.
    Khamis F; Al Arimi Z; Al Naamani H; Al Bahrani M; Pandak N; Al Bolushi Z; Deenadayalan SS; Al Lawati A; Al Salmi I; Al-Zakwani I
    Oman Med J; 2021 Sep; 36(5):e296. PubMed ID: 34631155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical Illness Due to Covid-19: A Description of the Surge in a Single Center in Sioux Falls.
    Jamous F; Meyer N; Buus D; Ateeli H; Taggart K; Hanson T; Alzoubaidi M; Nazir J; Devasahayam J
    S D Med; 2020 Jul; 73(7):312-317. PubMed ID: 32805781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) in critically ill pediatric patients admitted to the intensive care unit: A multicenter retrospective cohort study.
    Alfraij A; Bin Alamir AA; Al-Otaibi AM; Alsharrah D; Aldaithan A; Kamel AM; Almutairi M; Alshammari S; Almazyad M; Macarambon JM; Alghounaim M
    J Infect Public Health; 2021 Feb; 14(2):193-200. PubMed ID: 33486375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
    Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
    JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.
    Kocayiğit H; Demir G; Karacan A; Süner KÖ; Tomak Y; Yaylacı S; Dheir H; Kalpakci Y; Erdem AF
    Transfus Apher Sci; 2021 Aug; 60(4):103148. PubMed ID: 33962885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.